A5059330569- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Viral Infectious Diseases and Gene Expression in Insects
- Nanowire Synthesis and Applications
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Virus-based gene therapy research
- CRISPR and Genetic Engineering
- Neuroblastoma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
Wroclaw Medical University
2024
German Cancer Research Center
2019-2022
Heidelberg University
2019-2022
University Hospital Carl Gustav Carus
2017-2022
TU Dresden
2017-2022
Helmholtz-Zentrum Dresden-Rossendorf
2020-2022
Deutschen Konsortium für Translationale Krebsforschung
2020
German Cancer Society
2020
Antigen-specific redirection of immune effector cells with chimeric antigen receptors (CARs) demonstrated high therapeutic potential for targeting cancers different origins. Beside CAR-T cells, natural killer (NK) represent promising alternative effectors that can be combined CAR technology. Unlike T primary NK and the cell line NK-92 applied as allogeneic off-the-shelf products a reduced risk toxicities. We previously established modular universal (UniCAR) platform which consists...
As the expression of a tumor associated antigen (TAA) is commonly not restricted to cells, adoptively transferred T cells modified express conventional chimeric receptor (CAR) might only destroy but also attack target-positive healthy tissues. Furthermore, CAR in patients with large bulks will unpredictably proliferate and put at high risk adverse side effects including cytokine storms lysis syndrome. To overcome these problems, we previously established modular technology termed UniCAR:...
Induction or selection of radioresistant cancer (stem) cells following standard radiotherapy is presumably one the major causes for recurrence metastatic disease. One possibility to prevent tumor relapse application targeted immunotherapies including, e.g., chimeric antigen receptor (CAR) T cells. In light long-term remissions, it highly relevant clarify whether are susceptible CAR cell-mediated killing. To answer this question, we evaluated anti-tumor activity switchable universal (UniCAR)...
Since epithelial growth factor receptor (EGFR) overexpression is linked to a variety of malignancies, it an attractive target for immune therapy including chimeric antigen (CAR)-engineered T cells. Unfortunately, CAR cell harbors the risk severe, even life-threatening side effects. Adaptor platforms such as previously described UniCAR system might be able overcome these problems. In contrast conventional CARs, cells are per se inert. Their redirection towards occurs only in presence...
Abstract Recently, we established the controllable modular UniCAR platform technology to advance efficacy and safety of CAR T cell therapy. The system is composed (i) target modules (TMs) (ii) armed cells. TMs are bispecific molecules that able bind tumor surface simultaneously For interaction with cells, contain a peptide epitope sequence which recognised by So far, series against variety targets including prostate stem antigen (PSCA) were constructed functionally characterised. In order...
Most patients with head and neck squamous cell carcinomas (HNSCC) are diagnosed at a locally advanced stage show heterogeneous treatment responses. Low SLC3A2 (solute carrier family 3 member 2) mRNA protein (CD98hc) expression levels associated higher locoregional control in HNSCC treated primary radiochemotherapy or postoperative radiochemotherapy, suggesting that CD98hc could be target for radiosensitization. One of the targeted strategies tumor radiosensitization is precision...